ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,67%
Bitcoin
66 719,78
2,27%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cullinan Therapeutics Inc (CGEM)

  7. Cullinan Therapeutics Inc (CGEM) Actualités

CGEM

Cullinan Therapeutics (CGEM)

Cullinan Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CGEM
DateHeureSourceTitreSymboleSociété
16/05/202422h10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202413h30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412h42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412h40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
15/05/202422h05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
09/05/202401h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
06/05/202422h32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
29/04/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
24/04/202416h09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/04/202413h00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
16/04/202412h59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
14/03/202412h00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
01/03/202413h00GlobeNewswire Inc.Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaNASDAQ:CGEMCullinan Therapeutics Inc
27/02/202414h00GlobeNewswire Inc.Cullinan Oncology to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
15/02/202403h01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGEMCullinan Therapeutics Inc
08/01/202422h15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
08/01/202415h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
18/12/202322h53GlobeNewswire Inc.Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
14/12/202322h30GlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesNASDAQ:CGEMCullinan Therapeutics Inc
08/11/202313h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202313h00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
03/11/202317h01GlobeNewswire Inc.Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023NASDAQ:CGEMCullinan Therapeutics Inc
10/08/202313h00GlobeNewswire Inc.Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
09/08/202313h00GlobeNewswire Inc.Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaNASDAQ:CGEMCullinan Therapeutics Inc
03/08/202322h15PR Newswire (US)REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsNASDAQ:CGEMCullinan Therapeutics Inc
14/06/202322h36Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CGEMCullinan Therapeutics Inc
06/06/202322h10Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:CGEMCullinan Therapeutics Inc
25/05/202323h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CGEMCullinan Therapeutics Inc
25/05/202323h00GlobeNewswire Inc.Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023NASDAQ:CGEMCullinan Therapeutics Inc
11/05/202322h52Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:CGEMCullinan Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CGEM

Dernières Valeurs Consultées

LSE
EEP
Eastern European Property
LSE
14UX
Statnett 23
LSE
OTM
Ottoman Fund
NASDAQ
LDHA
LDH Growth Corporation I
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés